Argenx stock dips as FDA extends review period for subcutaneous efgartigimod

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

Argenx (NASDAQ:ARGX) said that the U.S. Food and Drug Administration (FDA) extended the review of its application seeking approval of subcutaneous (SC) efgartigimod to treat adult patients with generalized myasthenia gravis (gMG), to June 20.

The company had filed

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!